NB 506

Known as: NB-506 
 

Topic mentions per year

Topic mentions per year

1995-2005
05101519952005

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
Specific phosphorylation of serine- and arginine-rich pre-mRNA splicing factors (SR proteins) is one of the key determinants… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2001
2001
The antitumor drugs NB-506 and J-107088 are potent topoisomerase I inhibitors with an indolocarbazole structure. To clarify the… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2001
2001
Indolocarbazoles derived from the antibiotic rebeccamycin represent an important group of antitumor agents. Several… (More)
Is this relevant?
2001
2001
NB-506 is a topoisomerase I (top1) inhibitor in clinical trials. In this study, we used a series of camptothecin (CPT)-resistant… (More)
Is this relevant?
2000
2000
A novel competition dialysis method was used to study the structural selectivity of the nucleic acid binding of NB-506, a… (More)
Is this relevant?
1998
1998
An indolocarbazole compound, NB-506, inhibits the activity of topoisomerase I by stabilizing the DNA-topoisomerase I complex… (More)
Is this relevant?
1996
1996
Topoisomerase I-targeting anticancer agents such as 7-ethyl-10-[4-(1-piperidyl)-1-piperidyl]carbonyloxy-camptothecin (CPT-11) and… (More)
Is this relevant?
1995
1995
The novel anticancer glucosyl derivative of indolo-carbazole (NB-506), an inhibitor of DNA topoisomerase I, exhibited strong in… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
1995
1995
NB-506 [6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta-D- glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H… (More)
Is this relevant?
1995
1995
A new indolocarbazole antitumor agent, NB-506 [6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosyl) -5H… (More)
Is this relevant?